Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show

Exicure to Present at Upcoming Scientific Conferences

Exicure, Inc.® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNAtm) technology, today announced presentations at the following scientific conferences during the month of November:

Title: "Development of Spherical Nucleic Acids Targeting SCN9A For the Treatment of Neuropathic Pain"
Presented by: Bart Anderson, Senior Director, R&D
Date: November 16, 2021
Time: 8:45am CET / 1:45am U.S. CST

Neuroscience 2021 (The Society for Neuroscience)
Poster 1: "Spherical Nucleic Acids Targeting FXN Induce Frataxin Expression in Models of Friedreich's Ataxia"
Presented by: Grant Corbett, Group Lead, Neuroscience
Poster 2: "Biodistribution of Spherical Nucleic Acids in the Mouse CNS Following ICV, ICM and IT Delivery"
Presented by: Lauren Moore, Senior Scientist, Neuroscience
November 8-11, 2021

About Exicure, Inc.

Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on its proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure is in preclinical development of XCUR-FXN, a lipid-nanoparticle SNA?based therapeutic candidate, for the intrathecal treatment of Friedreich's ataxia (FA). Exicure's therapeutic candidate cavrotolimod (AST-008) is in a Phase 1b/2 clinical trial in patients with advanced solid tumors. Exicure is based in Chicago, IL and in Cambridge, MA. www.exicuretx.com

These press releases may also interest you

at 10:05
Applied DNA Sciences, Inc. (the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, announced today that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC...

at 10:05
Today, Eurofins (Paris:ERF) subsidiary empowerDX has launched PFAS Exposuretm in the United States, the first direct to consumer at-home test to determine levels of PFAS in a person's blood and measure 47 of the PFAS "forever chemical" compounds....

at 10:00
Zensights LLC is pleased to announce that Kris Ungvarsky has joined the organization as Principal, Head of Procurement Solutions. Kris is a seasoned, dynamic business leader who has driven sustainable growth for emerging biotech and...

at 10:00
The "Global Cardiac Arrest Treatment Market (2021-2026) by Treatment, Distribution Channel and Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering. The Global...

at 10:00
Mirati Therapeutics, Inc. , a clinical-stage targeted oncology company, today announced positive results from a Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib at the 600mg BID dose in patients with pretreated pancreatic ductal...

at 09:50
Breaking research published today in AACC's Clinical Chemistry journal shows that a new test can measure the amount of DNA damage in sperm with greater accuracy than current tests. This new method could significantly improve diagnosis of male...

News published on 28 october 2021 at 07:05 and distributed by: